Cytomedix‘s (OTC:CMXI) Aldagen acquisition signaled the company’s intention to establish a strong presence in regenerative medicine therapies and the deal fills needs for both companies. Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective [...]

A new treatment for cancer that uses artificial immune cells to trigger the body to kill cancerous cells will raise a series A round this spring and look to an investigational new drug (IND) application next year.NexImmune is an early stage biopharmaceutical company engineering artificial cells that can stimulate the immune system to treat cancer, [...]

Regenerative medicine company Cytomedix (OTC:CMXI) has acquired North Carolina stem cell technology company Aldagen in a stock deal valued at $40 million that broadens the firm’s regenerative therapies pipeline.Maryland-based Cytomedix develops biologically active regenerative therapies for wound care, inflammation and blood vessel development. The company has been diversifying to build its regenerative medicine capabilities. Aldagen’s [...]